US FDA approves Bayer's Sunharbo (asundexian) as first Factor XIa inhibitor for stroke prevention
What happened? On 9 November 2026, the US Food and Drug Administration approved BayerDealroom has a profile for this one. Try Dealroom →'s Sunharbo (asundexian) 50 mg tablets — the first approved medicine in a new class of blood thinners called Factor XIa inhibitors. The once-daily pill is taken alongside standard antiplatelet therapy to reduce the risk of another stroke in adults who have recently had a mild-to-moderate ischaemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischaemic attack, commonly called a "mini-stroke".
The evidence: The approval is based on the OCEANIC-STROKE Phase 3 trial, which enrolled 12,327 adults randomised to Sunharbo or placebo within 72 hours of symptom onset, both on top of antiplatelet therapy. Over a median treatment period of 14.2 months, Sunharbo reduced the risk of ischaemic stroke by 26% versus placebo. Overall major bleeding rates were similar, though bleeding was higher with Sunharbo in patients older than 75 and during the first 90 days of treatment, and gastrointestinal bleeding was more common. Diarrhoea was the most frequently reported side effect (3% or more of patients). The FDA granted Fast Track and Priority Review designations.
Why it matters: Stroke is a leading cause of death and long-term disability in the US, and people who survive one remain at elevated risk of a second. Factor XIa inhibitors aim to prevent clots with potentially lower bleeding risk than existing blood thinners, an area of intense industry development. The US approval follows a green light in China in early November 2026, making asundexian the first Factor XIa inhibitor approved anywhere in the world. Sunharbo is not approved for stroke prevention in patients with atrial fibrillation.
Read more: FDA, 9 November 2026 · Bayer, 9 November 2026